Current
45.7×
5-Year Average
33.8×
All-Time High
1446.6×
All-Time Low
9.5×
P/E Ratio daily chart for Edwards Lifesciences (EW)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/E Ratio for Edwards Lifesciences (EW) from 2001 to 2025
| 2025 | $49.48B | $1.07B | 46.2× | +35.8× | |
| 2024 | $43.66B | $4.17B | 10.5× | -22.4× | |
| 2023 | $46.15B | $1.40B | 32.9× | +2.9× | |
| 2022 | $45.73B | $1.52B | 30.0× | -23.7× | |
| 2021 | $80.85B | $1.50B | 53.8× | -15.3× | |
| 2020 | $56.88B | $823.40M | 69.1× | +22.6× | |
| 2019 | $48.71B | $1.05B | 46.5× | +2.4× | |
| 2018 | $31.87B | $722.20M | 44.1× | +5.9× | |
| 2017 | $23.76B | $622.10M | 38.2× | +3.0× | |
| 2016 | $20.02B | $569.50M | 35.2× | +0.7× | |
| 2015 | $17.04B | $494.90M | 34.4× | +17.6× | |
| 2014 | $13.68B | $811.10M | 16.9× | -1.6× | |
| 2013 | $7.18B | $389.80M | 18.4× | -16.9× | |
| 2012 | $10.37B | $293.20M | 35.4× | +1.3× | |
| 2011 | $8.07B | $236.70M | 34.1× | -8.0× | |
| 2010 | $9.18B | $218.00M | 42.1× | +20.7× | |
| 2009 | $4.90B | $229.10M | 21.4× | -2.4× | |
| 2008 | $3.07B | $128.90M | 23.8× | +0.7× | |
| 2007 | $2.61B | $113.00M | 23.1× | +2.3× | |
| 2006 | $2.71B | $130.60M | 20.7× | -10.5× | |
| 2005 | $2.48B | $79.30M | 31.3× | -1415.3× | |
| 2004 | $2.46B | $1.70M | 1446.6× | +1424.1× | |
| 2003 | $1.78B | $79.00M | 22.5× | -4.3× | |
| 2002 | $1.50B | $55.70M | 26.8× | — | |
| 2001 | $1.63B | −$12.00M | — | — |
- 202546.2×
- 202410.5×
- 202332.9×
- 202230.0×
- 202153.8×
- 202069.1×
- 201946.5×
- 201844.1×
- 201738.2×
- 201635.2×
- 201534.4×
- 201416.9×
- 201318.4×
- 201235.4×
- 201134.1×
- 201042.1×
- 200921.4×
- 200823.8×
- 200723.1×
- 200620.7×
- 200531.3×
- 20041446.6×
- 200322.5×
- 200226.8×
- 2001—
About P/E Ratio at Edwards Lifesciences (EW)
Edwards Lifesciences (EW) P/E ratio is 45.7× as of June 5, 2026. The 5-year average is 33.8×. The sector median currently stands at 25.0×. The current ratio is at the 82th percentile of its own 10-year history.
Edwards Lifesciences (EW) historical P/E ratio has ranged from a low of 9.5× (2024) to a high of 1446.6× (2004) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Edwards Lifesciences P/E Ratio by Year
Edwards Lifesciences P/E Ratio 2025: 46.2×
Edwards Lifesciences (EW) P/E ratio in 2025 was 46.2×, expanded from 10.5× the prior year.
Edwards Lifesciences P/E Ratio 2024: 10.5×
Edwards Lifesciences (EW) P/E ratio in 2024 was 10.5×, contracted from 32.9× the prior year.
Edwards Lifesciences P/E Ratio 2023: 32.9×
Edwards Lifesciences (EW) P/E ratio in 2023 was 32.9×, expanded from 30.0× the prior year.
Edwards Lifesciences P/E Ratio 2022: 30.0×
Edwards Lifesciences (EW) P/E ratio in 2022 was 30.0×, contracted from 53.8× the prior year.
Edwards Lifesciences P/E Ratio 2021: 53.8×
Edwards Lifesciences (EW) P/E ratio in 2021 was 53.8×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Edwards Lifesciences (EW), ranked by P/E ratio.
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Edwards Lifesciences (EW) Key Financials
Charts, filings, and peer comparison for every metric